Safety of Ruconest in 2-13 Year Old Hereditary Angioedema (HAE) Patients

Completed · Phase 2

Conditions studied: Hereditary Angioedema

In brief

This open-label study is being conducted to confirm the safety, pharmacokinetic profile and efficacy of Ruconest at a dose of 50 U/kg when used for the treatment of acute angioedema attacks in patients, from 2 up to and including 13 years of age.

Key facts

Study ID
NCT01359969
Run by
Pharming Technologies B.V.
People needed
57
Starts
2012-01-17
Expected to finish
2017-07-17
Last updated by the study team
2024-03-29

Who can join

Age: 2 and older, up to 13. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.